- Home
- / Alteogen
Alteogen
Stock Price
₩386 K
2024-10-29
Market Capitalization
₩20.2 T
2024-10-29
Revenue
₩215.9 B
FY, 2025
Alteogen Summary
Company Summary
- Overview
- Alteogen ((주)알테오젠) is a biopharmaceutical company that develops therapeutic proteins, antibody-drug conjugates (ADC), and monoclonal antibody biosimilars. It provides NexP fusion technology that supports the production of Human Growth Hormone (HGH), long-acting exenatide for diabetes, and long-acting Factor VIIa for haemophilia. Additionally, Alteogen provides NexMab ADC technology for targeted cancer therapy.
- Type
- Public
- Status
- Active
- Founded
- 2008
- HQ
- Daejeon, KR | view all locations
- Website
- http://www.alteogen.com/en/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Vivek Shenoy, CBO(Chief Business Development Officer)
Hangyeon Kim, CFO(Chief Financial Officer), Executive Vice President
Tae-Yon Chun, CAO(Corporate Alliance Officer), Executive Vice President
LocationsView all
2 locations detected
Daejeon, Daejeon HQ
Korea (Republic of)
62, Yuseong-daero 1628beon-gil, Yuseong-gu
Seoul, Seoul
Korea (Republic of)
room 1304, Hanshin It Tower 272
Alteogen Financials
Summary Financials
- Revenue (FY, 2025)
- ₩215.9B
- Gross profit (FY, 2025)
- ₩212.7B
- Net income (FY, 2025)
- ₩145.2B
- Cash (FY, 2025)
- ₩66.4B
- EBIT (FY, 2025)
- ₩151.3B
- Enterprise value
- $20.3T